Abstract
Abstract Based on the results of a phase I clinical trial announced at the 2012 Symposium on Molecular Targets and Cancer Therapeutics, an antibody—drug conjugate targeting prostate-specific membrane antigen may be an effective treatment for metastatic, hormone-refractory prostate cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
